Clinical Trials
Clinical Trial Tracker
Registered trials of peptide compounds, with phase, recruitment status, sponsor, enrollment, and primary endpoints. Search or filter to find any tracked trial.
Showing 2,572 of 2,572 tracked trials
- NCT07586150N/ANot Yet Recruiting
Personalized Pharmaco-Lifestyle Interventions for Severe Mental Illnesses (LIFETRAIN)
- Compound
- Semaglutide
- Sponsor
- Ludwig-Maximilians - University of Munich
- Enrollment
- 140
- Started
- Oct 2028
- NCT07382375N/ANot Yet Recruiting
AI-assisted Subtyping-directed Precision Treatment in Acute Aortic Dissection
- Compound
- Thymosin-Alpha-1
- Sponsor
- Nanjing Medical University
- Enrollment
- 300
- Started
- Dec 2027
- NCT07614412Phase 2Not Yet Recruiting
SHIELD-T1D: Shingrix and GLP-1 Agonist for Beta-Cell Preservation in Recent-Onset Type 1 Diabetes.
- Compound
- Semaglutide
- Sponsor
- Ministry of Health, Saudi Arabia
- Enrollment
- 240
- Started
- Jan 2027
- NCT06180616Phase 2Not Yet Recruiting
Tirzepatide for the Treatment of Concurrent Type 1 Diabetes and Overweight or Obesity
- Compound
- Tirzepatide
- Sponsor
- Royal North Shore Hospital
- Enrollment
- 40
- Started
- Dec 2026
- NCT07468552Phase 2Not Yet Recruiting
Trial of Tirzepatide for the Treatment of Cannabis Use Disorder
- Compound
- Tirzepatide
- Sponsor
- National Institute on Drug Abuse (NIDA)
- Enrollment
- 100
- Started
- Nov 2026
- NCT07609160N/ANot Yet Recruiting
Effectiveness of Combined GLP-1/GIP Dual Agonist Therapy and Structured Exercise on Skeletal Muscle Morphology, Quality, and Physical Function in Overweight and Obese Individuals
- Compound
- Tirzepatide
- Sponsor
- Acibadem University
- Enrollment
- 108
- Started
- Nov 2026
- NCT07027969Phase 4Not Yet Recruiting
Metabolic Surgery for Atrial Fibrillation Elimination
- Compound
- Tirzepatide
- Sponsor
- Ali Aminian
- Enrollment
- 100
- Started
- Nov 2026
- NCT07677891Phase 2Not Yet Recruiting
Phase II Study of Switching From Dulaglutide to PG-102(MG12) in Type 2 Diabetes Mellitus
- Compound
- Dulaglutide
- Sponsor
- ProGen. Co., Ltd.
- Enrollment
- 60
- Started
- Oct 2026
- NCT07642635Phase 1/Phase 2Not Yet Recruiting
Glucagon-Like Peptide-1 Receptor Agonists to Attenuate Metabolic Risk in Individuals With Duchenne Muscular Dystrophy
- Compound
- Semaglutide
- Sponsor
- Vanderbilt University Medical Center
- Enrollment
- 30
- Started
- Sep 2026
- NCT07622810Phase 3Not Yet Recruiting
BALANCE-OBS: Bofanglutide (GZR18) Versus Semaglutide in Latin American Adults With Overweight or Obesity
- Compound
- Semaglutide
- Sponsor
- Carnot Laboratories
- Enrollment
- 352
- Started
- Sep 2026
- NCT07617155Phase 4Not Yet Recruiting
GLP-1 Agonists for Prevention of Recurrent Hypertriglyceridemic Acute Pancreatitis
- Compound
- Semaglutide
- Sponsor
- Peking Union Medical College Hospital
- Enrollment
- 396
- Started
- Sep 2026
- NCT07509112Phase 2Not Yet Recruiting
Semaglutide for Treatment of People With Methamphetamine Use Disorder: the SHIFT Study
- Compound
- Semaglutide
- Sponsor
- Kirby Institute
- Enrollment
- 40
- Started
- Sep 2026
- NCT07668336Phase 3Not Yet Recruiting
A Study of Orforglipron (LY3502970) Compared With Dulaglutide in Pediatric Participants With Type 2 Diabetes
- Compound
- Dulaglutide
- Sponsor
- Eli Lilly and Company
- Enrollment
- 170
- Started
- Sep 2026
- NCT07357740Phase 2Not Yet Recruiting
A Research Study to Compare Two Different Versions of Injectable CagriSema in People With Type 2 Diabetes
- Compound
- Semaglutide
- Sponsor
- Novo Nordisk A/S
- Enrollment
- 400
- Started
- Aug 2026
- NCT06732245Phase 2Not Yet Recruiting
Safety and Efficacy of NA-931 and Tirzepatide in Adults Who Are Overweight or Obese
- Compound
- Tirzepatide
- Sponsor
- Biomed Industries, Inc.
- Enrollment
- 224
- Started
- Aug 2026
- NCT07282613Phase 3Not Yet Recruiting
A Research Study to See How Much CagriSema Lowers Blood Sugar and Body Weight Compared to Placebo in Children and Adolescents With Type 2 Diabetes
- Compound
- Semaglutide
- Sponsor
- Novo Nordisk A/S
- Enrollment
- 80
- Started
- Aug 2026
- NCT07671248Phase 3Not Yet Recruiting
Tirzepatide in the Treatment of Cannabis Use Disorder
- Compound
- Tirzepatide
- Sponsor
- McMaster University
- Enrollment
- 15
- Started
- Aug 2026
- NCT07676331Phase 2Not Yet Recruiting
Clinical Study of Local and Systemic Biological Impact of GLP1/GIP-Receptor Agonists in Patients With Breast Cancer: The CLARA Trial
- Compound
- Tirzepatide
- Sponsor
- Universitaire Ziekenhuizen KU Leuven
- Enrollment
- 168
- Started
- Aug 2026
- NCT07630454Phase 4Not Yet Recruiting
Tirzepatide on Atrial Fibrillation Recurrence After Catheter Ablation in Patients With Obesity and HFpEF
- Compound
- Tirzepatide
- Sponsor
- Yunlong Wang
- Enrollment
- 602
- Started
- Aug 2026
- NCT07592546Phase 4Not Yet Recruiting
Translational Health Research Into Vascular and Neurocognitive Effects of Weight Loss
- Compound
- Semaglutide
- Sponsor
- Alain Dagher
- Enrollment
- 240
- Started
- Aug 2026
- NCT07466498Phase 2Not Yet Recruiting
Estrogen to Improve Quality of Life for Men With Newly Diagnosed or Recurrent Metastatic Hormone Sensitive Prostate Cancer, EQUIP Trial
- Compound
- Gonadorelin
- Sponsor
- University of Washington
- Enrollment
- 60
- Started
- Aug 2026
- NCT07653282Phase 1/Phase 2Not Yet Recruiting
Effect of GnRH Agonist in FET
- Compound
- Gonadorelin
- Sponsor
- Assiut University
- Enrollment
- 122
- Started
- Aug 2026
- NCT07668765N/ANot Yet Recruiting
GLP-1 Receptor Agonists and Early Proctologic Effects in Morbid Obesity
- Compound
- Tirzepatide
- Sponsor
- Gazi University
- Enrollment
- 100
- Started
- Aug 2026
- NCT07671391Phase 2Not Yet Recruiting
A Randomized, Double-blind, Placebo-controlled Study Evaluating the Effect of LAE102 Injection in Combination With Tirzepatide on Body in Obese Participants
- Compound
- Tirzepatide
- Sponsor
- Shanghai Zhongshan Hospital
- Enrollment
- 60
- Started
- Aug 2026
- NCT07298915Phase 3Not Yet Recruiting
The Effect of Exercise and Tirzepatide on Weight and Health Outcomes (EXER-MED)
- Compound
- Tirzepatide
- Sponsor
- University of Virginia
- Enrollment
- 24
- Started
- Aug 2026
- NCT07078838Phase 2Not Yet Recruiting
Tirzepatide in Women With Obesity and Endometrial Intra-epithelial Neoplasia or Grade 1 Endometrial Cancer
- Compound
- Tirzepatide
- Sponsor
- UNC Lineberger Comprehensive Cancer Center
- Enrollment
- 40
- Started
- Aug 2026
- NCT07653477Phase 3Not Yet Recruiting
Phase III Study of UBT251 Injection in Patients With Type 2 Diabetes With Inadequate Glycemic Control on Metformin ± Sulfonylurea/SGLT2 Inhibitor Therapy (UNIGUIDE-2)
- Compound
- Semaglutide
- Sponsor
- The United Bio-Technology (Hengqin) Co., Ltd.
- Enrollment
- 956
- Started
- Jul 2026
- NCT07588438Phase 4Recruiting
Efficacy, Safety, and Tolerability of Tirzepatide in Real-World Conditions in Paraguay.
- Compound
- Tirzepatide
- Sponsor
- Las Rías Medical Center
- Enrollment
- 160
- Started
- Jul 2026
- NCT07349641Phase 2Not Yet Recruiting
A Study of Weight Loss Intervention With Tirzepatide and Progestin Intrauterine Device to Treat Endometrial Hyperplasia and Grade 1 Endometrial Cancer
- Compound
- Tirzepatide
- Sponsor
- National Cancer Institute (NCI)
- Enrollment
- 55
- Started
- Jul 2026
- NCT07635953Phase 3Not Yet Recruiting
New Triple Combination Therapy in Newly Diagnosed Type 2 Diabetes
- Compound
- Tirzepatide
- Sponsor
- Sun Yat-sen University
- Enrollment
- 296
- Started
- Jul 2026